Leadership changes at LEO Pharma

Privately-held Danish dermatology specialist LEO Pharma has appointed Kreesten Meldgaard Madsen as chief development officer and, effective Tuesday, he joined LEO Pharma’s global leadership team (GLT).

Dr Meldgaard Madsen joined LEO Pharma in 2016 with broad leadership and drug development experience from a number of R&D organizations. Most recently he held the position as head of R&D, Asia Pacific Hub. Further, he is an experienced medical doctor and has served at public hospitals, as a researcher and in the industry since he graduated in 1996. His scientific merits include a long list of scientific publications with more than 4,000 citations in international publications.

The appointment follows the announcements of organizational changes made in January and March 2023 when LEO Pharma split its R&D function into two new areas represented in the global Leadership Team, with Jacob Pontoppidan Thyssen appointed chief scientific officer and Dr Meldgaard Madsen now as chief development officer. The result is a more project focused organization, where late-stage projects will be brought closer to the GLT and the commercial organization allowing for a faster and more focused process from development to commercialization.